Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Understanding what long term capital gains tax rates are can help you manage your investments effectively. Learn the essentials to save more money.
28,035 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
As 2026 unfolds with economic and geopolitical headwinds, investors look to five Dividend Aristocrats for steady inco...
When a top executive sells a large block of shares, investors want clarity. This guide breaks down what RingCentral's...
G-III Apparel faces a pivotal year in 2026 as licensing momentum and margin discipline collide with shifting consumer...
Bloom Energy has climbed about 160% ytd, powered by a surge in AI-related data-center demand and new partnerships. Th...
As SpaceX eyes a historic float, investors are handed a high-stakes mix of dream-scale growth and sobering risk. This...
Artificial intelligence is reshaping how companies operate and compete. This guide highlights two standout AI stocks ...
Struggling to turn your money into a clear plan? This guide breaks down budgeting tools for financial planning, shows...
A $1,000 stake in Nvidia a decade ago would now command a large payoff, but the ride was anything but smooth. The sto...
Canopy Growth sits at the center of sharp investor debate. This article maps three plausible paths for the stock over...
MicroStrategy pauses BTC purchases, buys 1.5B face value of 0% notes due 2029 for about $1.38B, and shifts toward a b...
UBS boosts its price target on Xcel Energy to $89 while maintaining a Buy rating, saying the stock could year-end hig...